Doctor Anders Gaarsdal Holst

Anders Gaarsdal Holst, MD, PhD has a clinical and academic research background within cardiology with a focus on the epidemiology and genetics of arrhythmia. In the period 2013-2020 he worked at Novo Nordisk, latest as lead for cardiovascular clinical development across the portfolio of projects. In the position he was medically and scientifically responsible for leading both large cardiovascular outcomes trials as well as early stage clinical activities within the cardiovascular area. He has substantial experience in interacting with the FDA, EMA and other major regulatory authorities as well as with some of the world’s leading academic experts on steering committees and advisory boards. He has published more than 150 publications, many of them in leading journals. He is currently the CEO of Acesion Pharma, a company aiming to develop new drugs for atrial fibrillation.